Brachytherapy · 2024
Clinical outcomes of abbreviated high dose-rate brachytherapy in locally advanced cervical cancer: lessons from the COVID pandemic for high dose-rate fractionation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chopra Supriya, Samanta Asesh, Nagar Arunima, Mittal Prachi, Gupta Ankita, Mulani Jaahid, Jain Jeevanshu, Kohle Satish, Ghadi Yogesh, Rath Sushmita, Gulia Seema, Ghosh Jaya, Gupta Sudeep
Аннотация
PURPOSE: To evaluate outcomes of cervical cancer patients treated with abbreviated high dose rate brachytherapy (HDR-BT) that used 2-implants and delivered 4-5 fractions over 7-12 days rather than 21-28 days.
MATERIALS AND METHODS: Patients with stage IB2-IVA cervical cancer, treated with external beam radiation (EBRT) ± chemotherapy followed by abbreviated MR/CT-based HDR-BT were included. The planning aim was to achieve > 70Gy equivalent doses in 2Gy (EQD210Gy) at Point A dose in patients undergoing intracavitary BT (ICBT) and > 85Gy EQD210Gy to the HRCTV in intracavitary-interstitial BT (IC-ISBT). The dose constraints to 2 cc of bladder, rectum and sigmoid were restricted to < 90Gy3, < 75Gy3 and < 75Gy EQD23Gy respectively.
RESULTS: From 2020 to 2022, 245 patients were treated with EBRT followed by MR/CT-based HDR-BT. Median OTT was 57 days. The median HRCTV volume was 35.5cc with higher HRCTV in MR than CT-based (42.3cc vs. 32.8cc). The median dose to Point-A, HRCTV-D90, B2cc, R2cc and S2cc for ICBT was 78.1, 86.2, 87, 70.2 and 70.4Gy respectively. For IC-ISBT cohort, the median dose to HRCTV-D90, B2cc, R2cc, and S2cc was 86.1, 88.6, 70 & 66.7Gy respectively. The 3-years local control, pelvic control, locoregional, disease free and overall survival was 90%, 88%, 83.7%, 75.5% and 85% respectively. Late ≥ grade III gastrointestinal and genitourinary toxicities were 7.3% and 1.6% respectively with marginally higher toxicity in CT based cohort.
CONCLUSION: Accelerated HDR-BT schedule of 2-implants 4-5 fractions is radiobiological iso-effective and clinically safe with comparable oncological outcomes and adverse events.
MATERIALS AND METHODS: Patients with stage IB2-IVA cervical cancer, treated with external beam radiation (EBRT) ± chemotherapy followed by abbreviated MR/CT-based HDR-BT were included. The planning aim was to achieve > 70Gy equivalent doses in 2Gy (EQD210Gy) at Point A dose in patients undergoing intracavitary BT (ICBT) and > 85Gy EQD210Gy to the HRCTV in intracavitary-interstitial BT (IC-ISBT). The dose constraints to 2 cc of bladder, rectum and sigmoid were restricted to < 90Gy3, < 75Gy3 and < 75Gy EQD23Gy respectively.
RESULTS: From 2020 to 2022, 245 patients were treated with EBRT followed by MR/CT-based HDR-BT. Median OTT was 57 days. The median HRCTV volume was 35.5cc with higher HRCTV in MR than CT-based (42.3cc vs. 32.8cc). The median dose to Point-A, HRCTV-D90, B2cc, R2cc and S2cc for ICBT was 78.1, 86.2, 87, 70.2 and 70.4Gy respectively. For IC-ISBT cohort, the median dose to HRCTV-D90, B2cc, R2cc, and S2cc was 86.1, 88.6, 70 & 66.7Gy respectively. The 3-years local control, pelvic control, locoregional, disease free and overall survival was 90%, 88%, 83.7%, 75.5% and 85% respectively. Late ≥ grade III gastrointestinal and genitourinary toxicities were 7.3% and 1.6% respectively with marginally higher toxicity in CT based cohort.
CONCLUSION: Accelerated HDR-BT schedule of 2-implants 4-5 fractions is radiobiological iso-effective and clinically safe with comparable oncological outcomes and adverse events.